Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 26, 2001

View Archived Issues

SuperGen provides product update

Interim data from phase II mucositis trial presented by Access

MedImmune and Targesome establish agreement for Vitaxin development

Vertex pipeline update

Enrollment complete in pivotal trial of IM-862 in AIDS-related Kaposi's sarcoma

Arena completes acquisition of Bunsen Rush

Magainin receives patent for IL-9 antibody for treatment of asthma

BMS to spin-off Zimmer subsidiary

SR-7 disrupts G2/M transition via an apparently novel mechanism of action

Pharmacological activity of CS-747 is due to R-99224, a Gi-linked P2T antagonist

Caspase inhibitor prevents sepsis-associated cardiodepression in rat hearts

DCEBIO: a new benzimidazolone chloride secretion activator

Janssen completes phase III trials of sustained-release formulation of Risperdal

Iomed enrolls over 300 patients in phase III study for epicondylitis

Pain Therapeutics' phase II trial of PTI-601 now completely enrolled

Nabi StaphVAX elicits antibodies against resistant S. aureus strains

Two Nikken compounds selected for clinical testing

IGEN and the NCI begin cancer research program

Kirin accelerates development of NESP in Asia

Antisoma highlights recent product developments

Mochida presents new research in the area of anticoagulants

Synthesis and use of new chemokine receptor modulators described by AstraZeneca

Potential new agents for Alzheimer's disease designed at MIT

New antibacterial agents from Aventis possess activity against quinolone-resistant staphylococci

Japanese research group identifies new VEGF receptor antagonists

Treatment of T-cell-mediated diseases with new quinazoline derivatives

Adenosine A2A receptor antagonists synthesized at Vernalis for use in movement disorders

Antitumor effects of salvicine related to its ability to induce apoptosis

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 5, 2025.
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Mesothelin is biomarker, potential target in arthritic bone damage
BioWorld Science
In a recent study published in Cell Reports Medicine, researchers from the Institute of Chinese Materia Medica of the China Academy of Chinese Medical Sciences...
Gene therapies aim for the big goal of edits in vivo
BioWorld Science
The field of gene therapy is experiencing major advances driven by precise editing technologies, such as base and prime editing, and by the design of increasingly...